Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

Published:2024-04-28 Issue:1 Volume:35 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Soung Jennifer¹,Ständer Sonja²,Gutermuth Jan³,Pau-Charles Ignasi⁴,Dawson Zach⁵,Yang Fan Emily⁵,Sun Luna⁵,Pierce Evangeline⁵,Elmaraghy Hany⁵,Stein-Gold Linda⁶

Affiliation:

1. Southern California Dermatology, Inc, Santa Ana, CA, USA

2. University Hospital Westphalian Wilhems University, Munster, Germany

3. Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Jette, Belgium

4. Almirall, Barcelona, Spain

5. Eli Lilly and Company, Indianapolis, IN, USA

6. Clinic for Dermatology, Henry Ford Health System, Detroit, MI, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2024.2329240

Reference39 articles.

1. Atopic dermatitis

2. Comorbidities and the impact of atopic dermatitis

3. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association

4. Off-label prescriptions for atopic dermatitis in Europe

5. Eczema, atopy and allergen exposure in adults: a population-based study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP